华西医学

华西医学

晚期非小细胞肺癌长期生存患者临床特征及治疗相关因素分析

查看全文

目的 探讨晚期非小细胞肺癌长期生存患者的临床特征及治疗相关因素。 方法 对四川大学华西医院胸部肿瘤科 2010 年 1 月—2015 年 12 月收治的经病理学确诊且可供分析的 963 例Ⅳ期非小细胞肺癌患者的临床特征、治疗因素及生存情况进行回顾性分析。 结果 生存分析结果显示,963 例患者中位生存期为 20.8 个月,1、3、5、7 年生存率分别为 72.0%、21.4%、15.2%、4.8%。长期生存者(生存期>60 个月)81 例,非长期生存者(生存期<60 个月)882 例。既往手术、胸部放射治疗(放疗)以及表皮生长因子受体(epidermal growth factor receptor,EGFR)基因阳性显著影响 5 年实际存活率,分别降低死亡风险 62.0%、58.8%、58.1%。与非长期生存组相比,长期生存组内更多患者接受了包括手术、胸部放疗及靶向治疗在内的 2 种或 2 种以上手段(28.4% vs. 11.6%,P<0.001),长期生存组有更多患者在四线及以上的后线治疗中获益(24.7%vs. 11.1%,P<0.001)。Cox 多因素分析显示功能状态评分[风险比(hazard ratio,HR)=1.388,95% 置信区间(confidence interval,CI)(1.199,1.608),P<0.001]、N 分期[HR=1.160,95%CI(1.058,1.272),P=0.002]、EGFR 基因突变[HR=0.588,95%CI(0.469,0.738),P<0.001]、既往手术[HR=0.626,95%CI(0.471,0.832),P=0.001]、胸部放疗[HR=0.592,95%CI(0.480,0.730),P<0.001]是总生存期的独立影响因素(P<0.05)。 结论 功能状态评分、N 分期、EGFR 基因突变、既往手术及胸部放疗是影响晚期非小细胞肺癌患者生存的重要预后因素。多种治疗手段的综合治疗及后线治疗的持续获益有利于长期生存。

Objective To investigate the clinical features of non-small cell lung cancer (NSCLC) patients with long-term survival and the related factors for treatment. Methods A retrospective analysis of clinical features, treatment factors, and survival was performed for 963 patients with pathologically confirmed stage Ⅳ NSCLC between January 2010 and December 2015 from Department of Thoracic Oncology, West China Hospital, Sichuan University. Results The median overall survival (OS) of the 963 patients was 20.8 months, and the 1-, 3-, 5-, and 7-year survival rates were 72.0%, 21.4%, 15.2%, and 4.8%, respectively. There were 81 patients in the long-term survival group (OS>60 months) and 882 in the non-long-term survival group (OS<60 months). Previous surgery, thoracic radiotherapy and epidermal growth factor receptor (EGFR) gene positive significantly increased the 5-year actual survival rate, reducing the risk of death by 62.0%, 58.8%, and 58.1%, respectively. Compared with the non-long-term survival group, more patients in the long-term survival group received two or more means of treatment including surgery, thoracic radiotherapy, and targeted therapy (28.4% vs. 11.6%, P<0.001) and more patients benefited from fourth- or further-line treatment (24.7%vs. 11.1%, P<0.001). Cox multivariate regression analysis indicated that performance status [hazard ratio (HR)=1.388, 95% confidence interval (CI) (1.199, 1.608), P<0.001] , N stage [HR=1.160, 95%CI (1.058, 1.272), P=0.002] , EGFR gene status [HR=0.588, 95%CI (0.469, 0.738), P<0.001] , previous surgery [HR=0.626, 95%CI (0.471, 0.832), P=0.001] , and thoracic radiotherapy [HR=0.592, 95%CI (0.480, 0.730), P<0.001] were independent prognostic factors of OS. Conclusions Good performance status, early N staging, EGFR mutation, previous surgery, and thoracic radiotherapy are important prognostic factors affecting the survival of advanced NSCLC patients. Long-term survival benefits from combined treatment and effective further-line therapies.

关键词: 长期生存; 5 年生存率; 非小细胞肺癌; Ⅳ 期; 预后因素

Key words: Long-term survival; Five-year survival rate; Non-small cell lung cancer; Stage Ⅳ; Prognosis

引用本文: 秦舣, 黄媚娟, 李艳莹, 余敏, 刘兰, 任莉, 王永生, 宫友陵, 彭枫, 朱江, 丁振宇, 刘咏梅, 徐泳, 王瑾, 周晓娟, 卢铀. 晚期非小细胞肺癌长期生存患者临床特征及治疗相关因素分析. 华西医学, 2019, 34(1): 12-17. doi: 10.7507/1002-0179.201812075 复制

登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
2. 方积乾, 徐勇勇, 陈峰, 等. 卫生统计学. 7版. 北京: 人民卫生出版社, 2012: 419.
3. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
4. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11(1): 39-51.
5. 史国栋, 徐裕金, 孙晓江, 等. 转移性非小细胞肺癌患者不同生存期预后分析. 中国现代医生, 2013, 51(19): 10-12, 51.
6. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer, 2014, 15(5): 346-355.
7. de Vin T, Engels B, Gevaert T, et al. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol, 2014, 25(2): 467-471.
8. Yang CJ, Gu L, Shah SA, et al. Long-term outcomes of surgical resection for stage Ⅳ non-small-cell lung cancer: a national analysis. Lung Cancer, 2018, 115: 75-83.
9. Collen C, Christian N, Schallier D, et al. Phase Ⅱ study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol, 2014, 25(10): 1954-1959.
10. De Ruysscher D, Wanders R, van BA, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase Ⅱ trial (Nct01282450). J Thorac Oncol, 2012, 7(10): 1547-1555.
11. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014, 9(2): 154-162.
12. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
13. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
14. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8): 1723-1733.
15. Iyengar P, Kavanagh BD, Wardak Z, et al. Phase Ⅱ trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol, 2014, 32(34): 3824-3830.
16. 王春英, 程明, 汪德文, 等. 吉非替尼联合同步放疗治疗 EGFR 突变型转移性非小细胞肺癌的疗效及安全性. 中国肿瘤临床与康复, 2017(11): 1324-1327.
17. 汪丽, 谢金龙, 吴艳. 吉非替尼靶向介导在 sIMRT 治疗非小细胞肺癌中的应用分析. 临床肺科杂志, 2015, 20(8): 1377-1379, 1384.
18. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer. N Engl J Med, 2017, 377(20): 1919-1929.
19. Shaverdian N, Lisberg AE, Bornazyan KA, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017, 18(7): 895-903.